Triumph Capital Management Gritstone Bio, Inc. Transaction History
Triumph Capital Management
- $234 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding GRTS
# of Institutions
98Shares Held
45.6MCall Options Held
861KPut Options Held
4.52M-
Morgan Stanley New York, NY6.74MShares$3.84 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.79MShares$3.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA5.76MShares$3.28 Million0.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.73MShares$2.7 Million0.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA3.56MShares$2.03 Million12.76% of portfolio
About Gritstone bio, Inc.
- Ticker GRTS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,006,896
- Market Cap $41.6M
- Description
- Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...